Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH2 | P25021 | 1/20 | 0.40 |
| ▸ | HTR5A | P47898 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.35 |
| ▸ | TMIGD3 | P0DMS9 | 3/20 | 0.33 |
| ▸ | HTR2B | P41595 | 3/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29573820 | 0.90 | HRH2 (0.44) | HRH2HTR5AADORA3TMIGD3HTR2B | |
| SCHEMBL29573609 | 0.85 | ADORA3 (0.41) | HRH2HTR5AADORA3TMIGD3HTR2B | |
| SCHEMBL29573969 | 0.83 | HRH2 (0.54) | HRH2HTR5AADORA3TMIGD3HTR2B | |
| SCHEMBL29573468 | 0.71 | HTR2B (0.47) | ADORA3TMIGD3HTR2BADORA1HTR2C | |
| SCHEMBL29573869 | 0.71 | HRH2 (0.52) | HRH2HTR5AADORA3TMIGD3HTR2B | |
| SCHEMBL29573920 | 0.71 | HRH2 (0.52) | HRH2HTR5AADORA3TMIGD3HTR2B | |
| SCHEMBL29574457 | 0.69 | ADORA3 (0.54) | HRH2HTR5AADORA3TMIGD3HTR2B | |
| SCHEMBL29573977 | 0.69 | ADORA3 (0.45) | HRH2HTR5AADORA3TMIGD3HTR2B | |
| SCHEMBL29573779 | 0.68 | ADORA3 (0.48) | ADORA3TMIGD3HTR2BADORA1HTR2C | |
| SCHEMBL29573875 | 0.67 | HRH2 (0.53) | HRH2HTR5AADORA3TMIGD3HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4196219-A1 | A3 ADENOSINE RECEPTOR AGONISTS FOR USE IN MEDICINE | Biointervene, Inc. (US) | 2023-06-21 | — | — | EP | disclosed |
| WO-2022040241-A1 | A3 ADENOSINE RECEPTOR AGONISTS FOR USE IN MEDICINE | BIOINTERVENE, INC. (US) | 2022-02-24 | — | — | WO | disclosed |